Evidence map›Paper›PMID 36139072›Full record

ArticleBiomolecules2022

t

Yu Nagayoshi, Kayo Nishiguchi, Ryosuke Yamamura, Takeshi Chujo, Hiroyuki Oshiumi, Hiroko Nagata, Hitomi Kaneko, Keiichi Yamamoto, Hirotomo Nakata, Korin Sakakida and 11 more

Abstract read
In one paragraph

Article in Biomolecules, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. tRNA modifications in viral replication.The Journal of biological chemistry · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. mViruses · 2024
    Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Yu NagayoshiDepartment of Molecular Physiology, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan.
Kayo NishiguchiDepartment of Molecular Physiology, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan.
Ryosuke YamamuraDepartment of Molecular Physiology, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan.
Takeshi ChujoDepartment of Molecular Physiology, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan.ORCID 0000-0003-2393-5776
Hiroyuki OshiumiDepartment of Immunology, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan.
Hiroko NagataDepartment of Molecular Physiology, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan.
Hitomi KanekoDepartment of Molecular Physiology, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan.
Keiichi YamamotoDepartment of Laboratory Medicine, Kumamoto University Hospital, Kumamoto 860-8556, Japan.
Hirotomo NakataDepartment of Hematology, Rheumatology and Infectious Diseases, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan.
Korin SakakidaDepartment of Molecular Physiology, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan.
Akihiro KunisawaShimadzu Corporation, Kyoto 604-8442, Japan.
Masataka AdachiDepartment of Nephrology, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan.
Yutaka KakizoeDepartment of Nephrology, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan.
Takanori MizobeKumamoto Kenhoku Hospital, Kumamoto 865-8005, Japan.
Jun-Ichi KuratsuSakurajyuji Hospital, Kumamoto 861-4173, Japan.
Shinya ShimadaJCHO Kumamoto General Hospital, Kumamoto 866-8660, Japan.
Yasushi NakamoriDepartment of Emergency and Critical Care Medicine, Kansai Medical University General Medical Center, Osaka 570-8507, Japan.
Masao MatsuokaDepartment of Hematology, Rheumatology and Infectious Diseases, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan.
Masashi MukoyamaDepartment of Nephrology, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan.ORCID 0000-0001-5636-4039
Fan-Yan WeiDepartment of Modomics Biology and Medicine, Institute of Development Aging and Cancer, Tohoku University, Sendai 980-8575, Japan.
Kazuhito TomizawaDepartment of Molecular Physiology, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan.ORCID 0000-0002-5663-2627

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SARS-CoV-2 infection alters cellular RNA content. Cellular RNAs are chemically modified and eventually degraded, depositing modified nucleosides into extracellular fluids such as serum and urine. Here we searched for COVID-19-specific changes in modified nucleoside levels contained in serum and urine of 308 COVID-19 patients using liquid chromatography-mass spectrometry (LC-MS). We found that two modified nucleosides,

Indexed as

COVID-19NucleosidesAdenosineBiomarkersHumansRNASARS-CoV-2Threonine2-methylthio-N6-threonylcarbamoyladenosineAdenosineBiomarkersN(6)-(N-threonylcarbonyl)adenosineNucleosidesRNAThreonineCOVID-19LC-MSmodified nucleosides

Identifiers

PMID36139072
PMCPMC9496545

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.